日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years

年轻成人转移性乳腺癌的基因组图谱:一项针对20-40岁女性的液体活检分析

Diab, Ernest; Roussel-Simonin, Cyril; Giugliano, Federica; Dixon-Douglas, Julia; Spata, Alessandra; Pagliuca, Martina; Minot, Lauriane; Xu-Vuillard, Alexandre; Mosele, Fernanda; Grinda, Thomas; Viansone, Alessandro; Bousrih, Chayma; Zeghondy, Jean; Ben Ahmed, Tarek; Nicotra, Claudio; Bayle, Arnaud; Italiano, Antoine; Delaloge, Suzette; Pistilli, Barbara; André, Fabrice; Ribeiro, Joana; Rassy, Elie

How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer

人工智能在数字病理学中的应用如何指导乳腺癌的个性化治疗

Ruelle, T; Grinda, T; Del Mastro, L; Lacroix-Triki, M; Pistilli, B; Gessain, G

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer

在大型真实世界数据库中,根据生物标志物状态、治疗线数和既往是否接受过沙妥珠单抗戈维替康治疗,分析了曲妥珠单抗德鲁西替康治疗转移性乳腺癌患者的疗效

Tarantino, P; Lee, D; Foldi, J; Soulos, P R; Gross, C P; Grinda, T; Winer, E P; Lin, N U; Krop, I E; Tolaney, S M; Lustberg, M; Sammons, S

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

ESME-MBC队列中HR阳性/HER2阴性转移性乳腺癌患者在接受CDK4/6抑制剂治疗后疾病进展的真实世界治疗模式和疗效

Varnier, R; Pérol, D; Jacot, W; Mailliez, A; Diéras, V; Dalenc, F; Gonçalves, A; Levy, C; Arnedos, M; Frenel, J-S; Bailleux, C; Massard, V; Brain, E; Sauterey, B; Savoye, A-M; Bosquet, L; Thery, J-C; Petit, T; Bachelot, T; Grinda, T; Ray-Coquard, I

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer

接受sacituzumab govitecan治疗的转移性乳腺癌患者的生存结果及DNADX ctDNA检测的作用

Morganti, S; Kusmick, R J; Hughes, M E; Brasó-Maristany, F; Smith, K; Tarantino, P; Vega-Leon, R; Grinda, T; Pardo, F; Dvir, K; Suggs, G L; Buck, S; Skeffington, M; Garrido-Castro, A C; Parsons, H A; Sammons, S L; Prat, A; Lin, N U; Tolaney, S M; Giordano, A

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

乳腺癌中枢神经系统转移患者接受sacituzumab govitecan治疗的真实世界结果

Grinda, Thomas; Morganti, Stefania; Hsu, Liangge; Yoo, Tae-Kyung; Kusmick, Ross J; Aizer, Ayal A; Giordano, Antonio; Leone, Jose P; Hughes, Melissa; Tolaney, Sara M; Lin, Nancy U; Sammons, Sarah L

Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

抗体药物偶联物在乳腺癌中的应用:耐药机制及未来治疗前景

Valle, Irene; Grinda, Thomas; Antonuzzo, Lorenzo; Pistilli, Barbara

Invulnerability bias in perceptions of artificial intelligence's future impact on employment

对人工智能未来对就业影响的认知中存在的“无敌偏见”

Barrera-Jimenez, Felipe; Arroyo-Barrigüete, Jose Luis; Garrido-Merchán, Eduardo C; Grinda-Luna, Gonzalo

Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?

对于接受新辅助化疗的激素受体阳性乳腺癌患者,控制性卵巢刺激是否安全?

Benvenuti, C; Laot, L; Grinda, T; Lambertini, M; Pistilli, B; Grynberg, M

Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review

揭示细胞周期蛋白依赖性激酶 4 和 6 抑制剂在激素受体阳性/人表皮生长因子阴性晚期乳腺癌中超越疾病进展的潜在作用——一项临床综述

Benvenuti, Chiara; Grinda, Thomas; Rassy, Elie; Dixon-Douglas, Julia; Ribeiro, Joana M; Zambelli, Alberto; Santoro, Armando; Pistilli, Barbara